Parkinson's disease (PD) is a leading neurodegenerative health condition in Sweden and a public health concern. Although no cure exists, functional independence and participation in society remain top priorities, and can be achieved through targeted physical activity (PA) interventions. To date, few longitudinal cohort studies have been conducted, using PA as main outcome in therapy research, partly due to the complex nature of predicting and controlling this phenomenon. To help address this knowledge gap, the overall purpose of the future long-term (ActivPARK) study is to enhance knowledge of the evolution of PA behavior, and how it is influenced beyond the disease characteristics using a broad explanatory model, in persons with PD from a diversity of settings in Sweden with the aim of prescribing tailored and personalized interventions to enhance functioning, health, and wellbeing throughout the disease progression and recommend potential health care pathway modifications.
The investigators have just established an expert group, comprising researchers, healthcare professionals, and PD organisations (including persons with PD) and reached consensus on essential priority clinical therapy research questions on PA and methodological considerations. The next phase entails performing a multicentre feasibility/pilot study, further developing and refining the assessment battery and research questions linked to the improved explanatory model for PA and methodology, to inform the definite larger clinical cohort study.

Start Date25 Mar 2025

Sponsor / Collaborator

Karolinska Institutet

[+7]

NCT06774508

/ RecruitingNot Applicable

The Feasibility of a High-intensity Functional Exercise Program with Simultaneous Cognitive Challenge to Improve Physical and Cognitive Function in Older People with Intermediate Risk for Falls: a Randomized Controlled Pilot Trial

This study aims to evaluate the feasibility of a high-intensity functional exercise program with simultaneous cognitive challenge (HIFE+cog) among older people at risk of falls. The evaluation design and intervention development will be assessed with the following specific aims:
1. To investigate the acceptability and safety of the HIFE+cog program in older people at risk of falls, and the methods used in the study by evaluating recruitment, compliance with the intervention, severity of adverse events reported, and participant experiences.
2. To measure key outcome variables, including completion rates, missing data, estimates, variances, and 95% confidence intervals for between-group differences.
The study is designed as a randomized controlled pilot trial. Eligible participants will be randomized to either the intervention group (HIFE+cog) or the active control group (HIFE) to partake in individually tailored exercise, supervised and progressed by a physiotherapist, two times per week for 3 months.

Start Date17 Feb 2025

Sponsor / Collaborator

Umea Universitet

[+1]

NCT06814002

/ RecruitingNot Applicable

Networks Integrating Anxiety and Metabolism in Human Anorexia Nervosa, a Randomised Controlled Trial on Physiological and Psychological Responses to Caloric and Non-Caloric Meals

Anorexia nervosa (AN) is known as the psychiatric disorder with the highest mortality rate as long-term calorie restriction causes medical complications and suicide risk. The ineffectiveness of pharmacological treatments increases interest in the etiopathogenesis of the disease. This study aims to examine the effects of caloric and non-caloric food intake on stress response, changes in brain network activity in AN patients and healthy volunteers, and examine whether these changes are related to caloric intake through neuroendocrine and psychological responses.
The study will include 30 female AN patients aged 13-18 who are newly diagnosed and have not received any treatment, and 30 healthy volunteers matched by age, sex, and education level. The patient group will be admitted to the clinic's open inpatient unit on the evening before the study to ensure they have fasted. A 12-hour fasting period starting from the day before the procedure will be mandatory.
In the morning, patients will undergo psychiatric assessments and scales. Psychometric measurements will be applied to determine the clinical characteristics of participants. Visual Analog Scale (VAS) will be applied. VAS is used to evaluate subjective states such as hunger, satiety, desire to eat, anxiety, fear of obesity, sadness, appetite, general mood, and motivation to participate in the study. Following this, the first resting-state functional magnetic resonance imaging (fMRI) scan will be performed for 8 minutes.
Subsequently, participants will be randomised with 1:1 allocation ratio to consume one of two jellies prepared by a dietitian: one containing 400 calories and the other calorie-free. Participants will not be forced to consume the food.
The ingredients and preparation methods were chosen to make the appearance and taste of the foods similar. Participants will not know which type of food (caloric/non-caloric) they are given. Participants who do not wish to consume the provided food will be excluded from the study. Participants will be told that the mixture they will be consuming will either be balanced in nutritional value and caloric, or harmless and calorie-free. They will be given fifteen minutes to consume the mixture, and the amount they consume will be recorded. Sixty minutes after the consumption of the mixture, participants will undergo a second fMRI scan to identify the neuronal network changes induced by this process. The same procedures will be applied to the healthy control group. Before and after imaging, blood samples will be collected from participants for biochemical analysis. Endocrine markers such as glucose, insulin, ghrelin, obestatin, PYY, leptin, and cortisol will be evaluated to assess hunger, satiety, and stress responses. Changes in these parameters will be used to evaluate participants' physiological responses to meals. A second meal will be offered three hours after the first meal, and the amount consumed will be recorded.
Four subgroups will be analysed in the study: AN patients who received calories, AN patients who did not receive calories, healthy controls who received calories, and healthy controls who did not receive calories. Outcome data will be collected before and after meal intake and the outcomes will be compared between the four groups.
The study aims to investigate the physiological, psychological and behavioural responses to caloric and non-caloric meals, and to compare the responses in patients and non-patients. It is hypothesized that the stress response observed in AN patients is not solely related to food intake but that the calorie content of the ingested food will cause additional activation in biologically stress-related networks, with corresponding effects on experience. The hypothesis that the differences observed between patients and controls are due to biological differences in AN patients will be tested. This study aims to shed light on the etiopathogenesis of AN and contribute to the development of new strategies for the treatment and management of AN.

Start Date15 Feb 2025

Sponsor / Collaborator

Umea Universitet

100 Clinical Results associated with Umea Universitet

0 Patents (Medical) associated with Umea Universitet

56,378

Literatures (Medical) associated with Umea Universitet

31 Dec 2025·Global Health Action

A multilevel analysis on the predictors of client satisfaction with family planning services in Ethiopia: evidence from the Ethiopian service provision assessment (ESPA) 2021/22

Article

Author: Holmberg, Henrik ; Endale Mengesha, Michael

BACKGROUNDEthiopia has experienced growth in the utilization of family planning services. However, there are reports of relatively low client satisfaction across the country.OBJECTIVEThe objective of this study was to assess client and facility level predictors of satisfaction with family planning services in Ethiopia.METHODA multi-level mixed effects logistic regression analysis was conducted on a national survey obtained from the service provision assessment 2021-22. A total of 2071 clients (level one) and 529 facilities (level two) were included.RESULTSOverall, 56% of clients were highly satisfied with the family planning service they received. Findings from the random effects of the multilevel analysis show there is a significant difference in client satisfaction between facilities, with an intra-class correlation of 0.56 in the null model. At the client-level, age above 30, auditory privacy, and discussion on side effects are significantly associated with higher client satisfaction. At the facility level, having a waiting area, facilities with a quality unit and/or committee, a DHIS2 reporting system, operating for more than 20 days a month, privately owned facilities and availability of family planning guidelines are associated with higher odds of being satisfied. On the other hand, at the client level, having a primary or higher education, increasing wait time and clients asking their providers questions are associated with lower odds of being satisfied. At the facility level, having a fixed user fee significantly reduces the odds of client satisfaction.CONCLUSIONSHuman resource and professional development training and health system strengthening is recommended.

31 Dec 2025·Journal of Psychosomatic Obstetrics & Gynecology

Women’s desire to have a midwife they know during labor and birth has increased significantly over time

Article

Author: Lindqvist, Maria ; Hildingsson, Ingegerd ; Johansson, Margareta ; Holmlund, Sophia ; Fahlbeck, Hanna ; Larsson, Birgitta

BACKGROUNDIn Sweden, women often meet with different midwives during antenatal, intrapartum, and postpartum care, due to the structure of maternity care, with few alternatives which provide continuity. This study aims to explore women's interest in having a midwife they know present during labor and birth and to identify the characteristics of women who prefer this option.METHODSA comparative study was conducted involving two Swedish nationwide cohorts of Swedish-speaking pregnant women. The first cohort included 3,061 women, and the second 1,812 women. Descriptive statistics and odds ratios were calculated.RESULTSIn total, 4,873 pregnant women completed the survey. Most participants were aged 25-35 years, living with a partner, and born in Sweden. Interest in having a midwife they know increased from 53% in 1999 to 76% in 2024. Key factors associated with this preference included primiparity (OR 3.80; 95% CI 3.27-4.40), being pregnant in 2024 (OR 3.21; 2.70-3.86), being born outside Sweden (OR 2.73; 2.11-3.54), and fear of birth (OR 2.03; 1.56-2.63).CONCLUSIONSInterest in having a known midwife during childbirth has grown significantly in Sweden, highlighting the need for policy changes that promote awareness and expand this option for women.

31 Dec 2025·Cogent Education

Conditions and agency for multilingual students in higher education

Author: Dahlström, Helene ; Norberg, Malin

News (Medical) associated with Umea Universitet

08 Oct 2024

·www.medicaldesignandoutsourcing.com

Researchers develop medical vest to replace IV drip stands for kids

Nil Medical has developed a medical vest to help seriously ill children and adolescents with intravenous drip stands to regain their mobility. The company developed the ergonomic medical vest to conceal fluids, pumps and tubing within the garments, allowing children to play and move without restrictions. Nil Medical is currently conducting a national quality-of-life study in collaboration with Swedish healthcare to introduce it to the international market. “I learned about the challenge faced by children who are willing and able to play but are restricted in their movement due to being attached to an IV stand. After visiting the pediatric cancer ward, I felt inspired to address this issue using a user-centered design methodology,” said Martin Hanberger, an industrial design student at Norrlands Universitetssjukhus. ”It feels incredible to finally have a finished product after so many years of development – especially when we see how much the children appreciate it. Making things easier for them has always been our driving force”. The company developed an early prototype and tested it without being connected to any treatment or IV bags. After, a group of specialists in design, product development and CE marking of medical devices collaborated with experienced staff in the pediatric oncology department to develop the Nil Medical Vestpack. Researchers on the project established requirements and conducted risk analyses to ensure the vest was safe and user-friendly. Interviews with patients, families and healthcare providers were also integral to the development process. “One of the young users said, ‘I want it to be nothing,'” Hanberger said. “The name Nil (English for ‘zero’) was thus born from the freedom of movement that our medical vest provides. Those who use it no longer have to be confined to drip stands; instead, they can move freely, safely, and securely.” Quality of life study Nil Medical is conducting a quality of life study in Sweden for the Vestpack in collaboration with Region Jönköping, Sahlgrenska University Hospital, and Norrlands Universitetssjukhus. The goal is to introduce a CE-marked infusion vest to the international market, giving children new possibilities and greater freedom of movement. The company is developing the system and testing it in collaboration with the Umeå Biotech Incubator. “Umeå Biotech Incubator has extensive business development expertise, a solid reputation and track record, and a broad network of contacts,” Hanberger said. “We are really looking forward to start collaborating with UBI.”

03 Sep 2024

·quretech.com

QureTech Bio Announces the Appointment of Markus Thor as New CEO

QureTech Bio announces the appointment of Markus Thor as new CEO September 3, 2024 QureTech Bio, a biotechnology company developing novel antibiotics and anti-infectives, today announced that Markus Thor has been appointed as the new Chief Executive Officer, effective September 1, 2024. Markus Thor brings 30 years of experience from private and public pharmaceutical industry and biotech. He has a proven track record of successful leadership and business development in R&D focused biotech companies within a range of therapeutic areas. Previous roles include Chief Business Officer at XNK Therapeutics AB, Chief Business Officer at Kancera AB and Vice President & Head of Business Development at Biovitrum AB. He holds an MSc in Chemistry from Umeå University and an MBA from Stockholm School of Economics. Markus Thor replaces Helén Fält who is leaving upon her own request and will now start a new position as Commercial Manager at Apotek Produktion & Laboratorier (APL). “We are delighted to welcome Markus as the new CEO of QureTech Bio. He has the vision, expertise, and leadership skills to take the company to the next level of growth and success. We are confident that he will build on the strong foundation that Helén has established and lead QureTech Bio to achieve its full potential. We are also very grateful for everything that Helén has done for the company and wish her the best of luck with her new position,” says Lennart Hansson, Chairman of the Board of QureTech Bio. “We are delighted to welcome Markus as the new CEO of QureTech Bio. He has the vision, expertise, and leadership skills to take the company to the next level of growth and success. We are confident that he will build on the strong foundation that Helén has established and lead QureTech Bio to achieve its full potential. We are also very grateful for everything that Helén has done for the company and wish her the best of luck with her new position,” says Lennart Hansson, Chairman of the Board of QureTech Bio. Markus Thor on his new assignment: “I am honored and excited to join QureTech Bio, a company that is at the forefront of developing new and much needed solutions for the global health challenge of antimicrobial resistance. I look forward to working with the team, the board, and our partners to advance the company’s pipeline into the clinical stage and bring novel therapies to patients in need”. “I am honored and excited to join QureTech Bio, a company that is at the forefront of developing new and much needed solutions for the global health challenge of antimicrobial resistance. I look forward to working with the team, the board, and our partners to advance the company’s pipeline into the clinical stage and bring novel therapies to patients in need”. Contact Lennart Hansson, Chairman of the Board E-post: lennart@ignitus.se Mobil: +46 70-631 00 31 Web: www.quretech.com About QureTech Bio AB is a pharmaceutical development company with a focus on developing new solutions to combat disease-causing bacteria and thereby contribute with new alternatives to one of our times’ greatest threats to modern healthcare, antimicrobial resistance (AMR). The company’s lead program is focused on developing a new class of antibiotics, called GmPcides, that are effective against multidrug resistant Gram-positive bacteria. QTB is located in Umeå, which is one of Sweden’s prominent life science clusters. Pressrelease_New CEO_Aug 2024

Executive Change

03 Jul 2024

·quretech.com

QureTech Bio appoints new Chairman of the Board and new Board Member

QureTech Bio appoints new Chairman of the Board and new Board Member June, 2024 QureTech Bio AB, a biotech company that develops novel antibiotics, has announced the appointment of Lennart Hansson as its new Chairman of the Board. Hansson succeeds Sven Bergström, who is stepping down after a successful tenure leading the company’s strategic direction. “I have been a Member of the Board for one year and am honored to join QureTech as the Chairman of the Board. I am impressed by the science behind it, and I believe they have a unique and innovative approach to tackling the urgent problem of antimicrobial resistance. I look forward to working with the management team and the board to support QureTech’s growth and success,” says Lennart Hansson. “I have been a Member of the Board for one year and am honored to join QureTech as the Chairman of the Board. I am impressed by the science behind it, and I believe they have a unique and innovative approach to tackling the urgent problem of antimicrobial resistance. I look forward to working with the management team and the board to support QureTech’s growth and success,” says Lennart Hansson. He is the former head of Life Science Investments at Industrifonden, one of Sweden’s largest venture funds. Previously he has more than 30 years’ experience in the pharma and biotech industry in executive positions at KabiGen, Symbicom AB, AstraZeneca AB, Karolinska Development AB, and BioVitrum AB and as CEO for Arexis AB. He has a PhD in Genetics from Umeå University. Other current assignments: Hansson is Chairman of the Board of Cinclus Pharma Holding AB, Sixera Pharma AB, and Ignitus AB, as well as Board Member of Medivir AB. “We thank Sven Bergström for his great contribution to QureTech over the years and welcome Lennart Hansson as new chairman. His longtime experience and expertise in business development will have an impact for the future development of the company” said Helén Fält, the CEO of QureTech. “We thank Sven Bergström for his great contribution to QureTech over the years and welcome Lennart Hansson as new chairman. His longtime experience and expertise in business development will have an impact for the future development of the company” said Helén Fält, the CEO of QureTech. Additionally, QureTech has elected Professor Scott Hultgren, co-founder and a world-renowned expert in bacterial infections and drug discovery, as a new Board Member. Hultgren is the Helen Lehbrink Stoever Professor of Molecular Microbiology at Washington University in St. Louis where he also serves as the inaugural Director of the Center for Women’s Infectious Disease Research. “Scott Hultgren is a great addition to our Board. He has made groundbreaking contributions to the field of bacterial pathogenesis and has a deep understanding of the challenges and opportunities in developing new antimicrobials. His scientific insights and entrepreneurial spirit will be invaluable for QureTech as we advance our pipeline of novel compounds,” said Helén Fält, the CEO of QureTech. “Scott Hultgren is a great addition to our Board. He has made groundbreaking contributions to the field of bacterial pathogenesis and has a deep understanding of the challenges and opportunities in developing new antimicrobials. His scientific insights and entrepreneurial spirit will be invaluable for QureTech as we advance our pipeline of novel compounds,” said Helén Fält, the CEO of QureTech. Professor Hultgren has been honored with several prestigious awards, including the Distinguished Investigator Award at Washington University, the Eli Lilly Microbiology Award, and “The Fellows Award” from the St. Louis Science Academy, recognizing his outstanding scientific achievements. He was elected to the American Association for the Advancement of Science in 2009, the National Academy of Sciences in 2011, the National Academy of Medicine in 2017, the National Academy of Inventors in 2020, and the American Academy of Arts and Sciences in 2023. The Hultgren lab is blending multiple scientific disciplines to elucidate bacterial and host mechanisms that determine the onset, course, and outcome of interactions between the host urinary tract and bacterial pathogens. The QureTech Bio Board Lennart Hansson, Chairman Erik Gozzi Fredrik Almqvist Scott Hultgren Ulf Björklund Yijing Sun Hultgren Contact Helén Fält, VD E-post: helen.falt@quretech.com Mobil: +46 70 388 5025 Web: www.quretech.com About Pressrelease_new chairman and board member_240703

Executive Change

100 Deals associated with Umea Universitet

100 Translational Medicine associated with Umea Universitet

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 09 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 3 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

[18F]PSMA-PET	Prostatic Cancer More	Phase 3
C-10	Tuberculosis More	Preclinical
Mycobacterium tuberculosis inhibitors(Umea Universitet)	Tuberculosis More	Preclinical
APD-514	Adenoviridae Infections More	Discontinued
UCM-03025 ( MAGL )	Multiple Sclerosis More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis